Trial · NCT01727336
Results by group33
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 33
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Part 1: Number of Participants With Adverse Events as a Measure of Safety and Tolerability. | Part 1 Dalantercept 0.6 mg/kg | 6 | Participants | ||
| Part 1: Number of Participants With Adverse Events as a Measure of Safety and Tolerability. | Part 1 Dalantercept 0.9 mg/kg | 9 | Participants | ||
| Part 1: Number of Participants With Adverse Events as a Measure of Safety and Tolerability. | Part 1 Dalantercept 1.2 mg/kg | 14 | Participants | ||
| Part 2: Progression Free Survival (PFS). | Part 2: Dalantercept 0.9 mg/kg Plus Axitinib | 6.8 | 95% Confidence Interval 4.5 to 9.4 | Months | |
| Part 2: Progression Free Survival (PFS). | Part 2: Placebo Plus Axitinib | 5.6 | 95% Confidence Interval 3.3 to 8.3 | Months | |
| Part 1: Progression Free Survival (PFS). | Part 1 Dalantercept 0.6 mg/kg | 5.5 | 95% Confidence Interval 1.3 to 20.6 | Months | |
| Part 1: Progression Free Survival (PFS). | Part 1 Dalantercept 0.9 mg/kg | 21.6 | 95% Confidence Interval 2.8 to 21.6 | Months | |
| Part 1: Progression Free Survival (PFS). | Part 1: Dalantercept 1.2 mg/kg | 6.9 | 95% Confidence Interval 2.7 to 20.7 | Months | |
| Part 1: Overall Survival (OS). [The Time Frame for Part 1 of the Study Was up to 21.6 Months] | Part 1 Dalantercept 0.6 mg/kg | 4 | Participants | ||
| Part 1: Overall Survival (OS). [The Time Frame for Part 1 of the Study Was up to 21.6 Months] | Part 1 Dalantercept 0.9 mg/kg | 7 | Participants | ||
| Part 1: Overall Survival (OS). [The Time Frame for Part 1 of the Study Was up to 21.6 Months] | Part 1: Dalantercept 1.2 mg/kg | 9 | Participants | ||
| Part 1: Objective Response Rate (ORR) | Part 1 Dalantercept 0.6 mg/kg | 2 | Participants | ||
| Part 1: Objective Response Rate (ORR) | Part 1 Dalantercept 0.9 mg/kg | 3 | Participants | ||
| Part 1: Objective Response Rate (ORR) | Part 1: Dalantercept 1.2 mg/kg | 2 | Participants | ||
| Part 1: Disease Control Rate (DCR) | Part 1 Dalantercept 0.6 mg/kg | 3 | Participants | ||
| Part 1: Disease Control Rate (DCR) | Part 1 Dalantercept 0.9 mg/kg | 5 | Participants | ||
| Part 1: Disease Control Rate (DCR) | Part 1: Dalantercept 1.2 mg/kg | 6 | Participants | ||
| Part 1: Duration of Response (DoR) | Part 1 Dalantercept 0.6 mg/kg | 3 | 95% Confidence Interval 2.8 to 21.6 | months | |
| Part 1: Duration of Response (DoR) | Part 1 Dalantercept 0.9 mg/kg | 6.9 | 95% Confidence Interval 6.9 to 21.6 | months | |
| Part 1: Duration of Response (DoR) | Part 1: Dalantercept 1.2 mg/kg | 10 | 95% Confidence Interval 8.8 to 11.1 | months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01727336/results